(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 20.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Alnylam Pharmaceuticals's revenue in 2026 is $4,804,182,000.On average, 33 Wall Street analysts forecast ALNY's revenue for 2026 to be $748,260,587,856, with the lowest ALNY revenue forecast at $699,286,450,668, and the highest ALNY revenue forecast at $810,080,400,372. On average, 33 Wall Street analysts forecast ALNY's revenue for 2027 to be $948,171,410,148, with the lowest ALNY revenue forecast at $803,791,371,826, and the highest ALNY revenue forecast at $1,117,573,753,536.
In 2028, ALNY is forecast to generate $1,132,694,183,870 in revenue, with the lowest revenue forecast at $867,618,321,112 and the highest revenue forecast at $1,394,157,200,442.